论文部分内容阅读
目的探讨乳腺癌TOPOⅡα、HER-2蛋白表达与蒽环类药物新辅助化疗疗效之间的关系。方法通过免疫组化(IHC)方法检测50例乳腺癌患者TOPOⅡα及HER-2蛋白的表达,分析TOPOⅡα和HER-2蛋白表达与临床病理疗效的关系、TOPOⅡα与HER-2表达的相关性及联合表达与临床病理疗效之间的关系。结果 50例乳腺癌患者中,TOPOⅡα蛋白表达17例,阳性率为34%(17/50),TOPOⅡα表达组的临床及病理有效率均优于TOPOⅡα未表达组(P<0.05)。TOPOⅡα与HER-2的表达具有相关性(P<0.05),HER-2及TOPOⅡα共同表达的病例为12例,但经相关性分析蒽环类药物新辅助化疗效果无明显差异(P>0.05)。结论乳腺癌组织中TOPOⅡα蛋白表达与HER-2蛋白表达具有相关性,TOPOⅡα蛋白表达对基于蒽环类药物的新辅助化疗的疗效预测有正相关作用。
Objective To investigate the relationship between the expression of TOPOⅡα and HER-2 in breast cancer and the efficacy of anthracycline neoadjuvant chemotherapy. Methods Immunohistochemistry (IHC) was used to detect the expression of TOPOⅡα and HER-2 protein in 50 cases of breast cancer. The relationship between the expression of TOPOⅡα and HER-2 protein and the clinicopathological effect was analyzed. The correlation between TOPOⅡα and HER-2 expression and their association Expression and clinicopathological effects of the relationship between. Results TOPOⅡα protein expression was found in 17 of 50 breast cancer patients, the positive rate was 34% (17/50). The clinical and pathological efficiency of TOPOⅡα expression group was better than that of TOPOⅡα non-expression group (P <0.05). The expression of TOPOⅡα and HER-2 were correlated (P <0.05). The co-expression of HER-2 and TOPOⅡα was 12 cases, but there was no significant difference between the two groups in the effect of neoadjuvant chemotherapy (P> 0.05) . Conclusion The expression of TOPOⅡα protein in breast cancer tissue is correlated with the expression of HER-2 protein. The expression of TOPOⅡα protein has a positive correlation with anthracycline-based neoadjuvant chemotherapy.